Vyant Bio, Inc.

Industry

  • Digital Health
    • Artificial Intelligence
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Chemistry, Immunoassay
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals

Other Names/Subsidiaries

  • Bio Type, Inc.
  • Cancer Genetics, Inc.
  • Gentris Corporation
  • Pathwork Diagnostics
  • Response Genetics, Inc.
  • StemoniX Inc.
  • vivoPharm Pty. Ltd.
See more in Biomedtracker

Latest on Vyant Bio, Inc.

Scrip

Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis And Ionis Build On Earlier Akc

Scrip

Ordaõs Looks To Unlock The Therapeutic Promise Of Mini-Proteins

 
• By Joseph Haas

From research into the single-chain antibody structures found in camelids (camels and other animals), Ordaos Bio is trying to harness the potential of mini-proteins, a new category that combines som

Scrip

Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf

 
• By Joseph Haas and Vibha Ravi

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Jazz Moves Into IO With Engineered IFN⍺

Scrip

Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. NewAmsterdam’s Plans For Obicetrapib In